Deva Holding AS (DEVA) - Total Assets
Based on the latest financial reports, Deva Holding AS (DEVA) holds total assets worth TL35.50 Billion TRY (≈ $795.16 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Deva Holding AS to assess how comfortably operating cash covers total debt obligations.
Deva Holding AS - Total Assets Trend (2005–2024)
This chart illustrates how Deva Holding AS's total assets have evolved over time, based on quarterly financial data. See Deva Holding AS book value and equity for net asset value and shareholders' equity analysis.
Deva Holding AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Deva Holding AS's total assets of TL35.50 Billion consist of 41.3% current assets and 58.7% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 3.2% |
| Accounts Receivable | TL4.93 Billion | 16.6% |
| Inventory | TL4.73 Billion | 15.9% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL5.86 Billion | 19.7% |
| Goodwill | TL30.86 Million | 0.1% |
Asset Composition Trend (2005–2024)
This chart illustrates how Deva Holding AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Deva Holding AS (DEVA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Deva Holding AS's current assets represent 41.3% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, up from 2.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 4.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 19.7% of total assets.
Deva Holding AS Competitors by Total Assets
Key competitors of Deva Holding AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS
|
India | Rs51.59 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
China | CN¥1.95 Billion |
Deva Holding AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.71 | 1.57 | 1.97 |
| Quick Ratio | 1.06 | 0.95 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL6.02 Billion | TL4.49 Billion | TL961.62 Million |
Deva Holding AS - Advanced Valuation Insights
This section examines the relationship between Deva Holding AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -8.3% |
| Total Assets | TL29.73 Billion |
| Market Capitalization | $336.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Deva Holding AS's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Deva Holding AS's assets decreased by 8.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Deva Holding AS (2005–2024)
The table below shows the annual total assets of Deva Holding AS from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL29.73 Billion ≈ $665.86 Million |
-8.26% |
| 2023-12-31 | TL32.40 Billion ≈ $725.77 Million |
+275.73% |
| 2022-12-31 | TL8.62 Billion ≈ $193.16 Million |
+69.77% |
| 2021-12-31 | TL5.08 Billion ≈ $113.78 Million |
+64.51% |
| 2020-12-31 | TL3.09 Billion ≈ $69.16 Million |
+45.69% |
| 2019-12-31 | TL2.12 Billion ≈ $47.47 Million |
+27.03% |
| 2018-12-31 | TL1.67 Billion ≈ $37.37 Million |
+32.79% |
| 2017-12-31 | TL1.26 Billion ≈ $28.14 Million |
+23.48% |
| 2016-12-31 | TL1.02 Billion ≈ $22.79 Million |
+2.47% |
| 2015-12-31 | TL992.95 Million ≈ $22.24 Million |
+11.13% |
| 2014-12-31 | TL893.53 Million ≈ $20.01 Million |
+8.09% |
| 2013-12-31 | TL826.63 Million ≈ $18.51 Million |
+14.29% |
| 2012-12-31 | TL723.26 Million ≈ $16.20 Million |
+8.56% |
| 2011-12-31 | TL666.25 Million ≈ $14.92 Million |
+6.98% |
| 2010-12-31 | TL622.80 Million ≈ $13.95 Million |
+17.86% |
| 2009-12-31 | TL528.42 Million ≈ $11.84 Million |
+7.89% |
| 2008-12-31 | TL489.79 Million ≈ $10.97 Million |
+27.13% |
| 2007-12-31 | TL385.28 Million ≈ $8.63 Million |
+32.45% |
| 2006-12-31 | TL290.88 Million ≈ $6.52 Million |
+6.48% |
| 2005-12-31 | TL273.18 Million ≈ $6.12 Million |
-- |
About Deva Holding AS
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and … Read more